BioSpace News Archive

Imara Inc. today announced that it will present clinical and preclinical data at the American Society of Hematology (ASH) Annual Meeting to be held December 11-14, 2021.

Arcellx, Inc. today announced the presentation of new Phase 1 clinical trial data of its CART-ddBCMA for the treatment of patients with relapsed and refractory multiple myeloma.

EIP Pharma Inc. data will be presented at the 14th Clinical Trials in Alzheimer’s Disease (CTAD) meeting that will be held in Boston November 9th through 12th, 2021.

As part of its commitment to reducing burdens facing the rare disease community, Takeda Pharmaceutical Company Limited announced three priority policy reforms and solutions designed to address significant barriers to care for patients managing rare diseases and genetic conditions as part of a new report, “Reducing Time to Diagnosis for People Living with Rare Diseases: A Conversation on U.S. Policy Opportunities.”

BioInvent International AB today announces additional positive interim top-line data from its novel anti-FcγRIIB antibody BI-1206.

TScan Therapeutics, Inc. today announced that two abstracts related to its lead liquid tumor candidates TSC-100 and TSC-101 have been accepted for poster presentations at the upcoming American Society of Hematology (ASH) Annual Meeting and Exposition, being held from December 11-14, 2021.

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its diverse hematology program in blood cancers and disorders will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting from December 11-14 in Atlanta, GA.

Vivera Pharmaceuticals announced that Sahar S. Pugh will join the Company as General Counsel and Vice President of Legal Affairs.

EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces the appointment of Dr. Marwan Sabbagh as non-executive director to its Board of Directors with immediate effect.